What dosage do you plan on starting with? This stuff has my ears perked up as my wife suffers from nerve pain!!Bro, I too have been searching for this for my wife. I will say that ALA and curcumin has helped but I think we are going to try ARA 290. Gabapentin helps for sure but I think if she can reduce the nerve inflammation she can get even more relief.
“This phase 2b, 28-day, randomized trial of 64 subjects with sarcoid-associated SNFL [small nerve fiber loss] and neuropathic pain assessed the effect of cibinetide on corneal nerve fiber area (CNFA) and regenerating intraepidermal fibers (GAP-43+) as surrogate endpoints for disease modification, pain severity, and functional capacity”
“…Pain improved significantly in all groups, with subjects having moderate-severe pain reporting a clinically meaningful placebo-corrected decrease in pain intensity in the 4 mg group” (Source)
“The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in small fiber neuropathy screening list score compared with placebo.”
Additionally, the ARA 290 group showed a significant change from baseline in the pain and physical functioning dimensions of the SF-36. The mean Brief Pain Inventory and Fatigue Assessment Scale scores improved significantly but equivalently in both patient groups” (Source)
Bro, I too have been searching for this for my wife. I will say that ALA and curcumin has helped but I think we are going to try ARA 290. Gabapentin helps for sure but I think if she can reduce the nerve inflammation she can get even more relief.
“This phase 2b, 28-day, randomized trial of 64 subjects with sarcoid-associated SNFL [small nerve fiber loss] and neuropathic pain assessed the effect of cibinetide on corneal nerve fiber area (CNFA) and regenerating intraepidermal fibers (GAP-43+) as surrogate endpoints for disease modification, pain severity, and functional capacity”
“…Pain improved significantly in all groups, with subjects having moderate-severe pain reporting a clinically meaningful placebo-corrected decrease in pain intensity in the 4 mg group” (Source)
“The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in small fiber neuropathy screening list score compared with placebo.”
Additionally, the ARA 290 group showed a significant change from baseline in the pain and physical functioning dimensions of the SF-36. The mean Brief Pain Inventory and Fatigue Assessment Scale scores improved significantly but equivalently in both patient groups” (Source)
There are currently 0 members watching this topic